| CASE REPORT |
|
| Year : 2011 | Volume
: 5
| Issue : 1 | Page : 6-8 |
|
|
C5b-9 inhibitor (eculizumab) for antibody-mediated rejection in renal transplantation
Rizwan Hamer1, Nithya Krishnan2, David Lowe3, David Briggs3, Daniel Zehnder1, Robert Higgins2
1 Transplant Unit; Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry, West Midlands, UK
2 Transplant Unit, University Hospitals Coventry and Warwickshire, Coventry, West Midlands, United Kingdom
3 Histocompatibility Laboratory, NHS Blood and Transplant, Birmingham, West Midlands, United Kingdom
Correspondence Address:
Rizwan Hamer
Renal unit University hospitals Coventry and Warwickshire CV2 2DX
UK
 Source of Support: None, Conflict of Interest: None
|
|
|
Increasingly successful protocols enabling HLA antibody incompatible renal transplantation have resulted in a rise in the incidence of antibody mediated rejection. There are limited options to treat this feared complication. Eculizumab, a potent inhibitor of the complement cascade, has recently been suggested as a possible addition to treatment of AMR. We report the use of eculizumab in three very high risk transplant recipients.
|
|
|
|
| [PDF]* |
|
 |
|
